Drug Pipeline
Subscribe to Drug Pipeline
View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Marijuana Pill, Spray May Ease Some MS Symptoms

March 25, 2014 1:37 pm | News | Comments

A new guideline from the American Academy of Neurology states that oral cannabis, or medical marijuana pills, and oral medical marijuana spray may ease the symptoms of multiple sclerosis (MS). Read more...          

Pfizer's Xalkori Extends Lung Cancer Survival

March 25, 2014 1:28 pm | News | Comments

Pfizer announced that PROFILE 1014, a Phase 3 study of anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib), met its primary objective of significantly prolonging progression-free survival (PFS) when compared to standard platinum-based chemotherapy regimens. Read more...

Ferrer, Medimetriks in Licensing Agreement for Impetigo Drug

March 25, 2014 11:20 am | News | Comments

Medimetriks Pharmaceuticals Inc. announced a licensing agreement with Ferrer for the commercialization rights to Ozenoxacin 1% Cream in the United States. Ozenoxacin is a novel, bactericidal non-fluorinated quinolone in development as a topical treatment for impetigo. Read more...


Takeda Hypertension Drug Gets OK in Japan

March 25, 2014 11:05 am | News | Comments

Takeda announced that the Japanese Ministry of Health, Labor and Welfare has approved the New Drug Application of Zacras tablets for treatment of hypertension. Read more...                       

Daiichi's Antiplatelet Agent Approved in Japan

March 25, 2014 10:52 am | News | Comments

Daiichi Sankyo Co. Ltd. announced that it has received approval from the Ministry of Health, Labor and Welfare in Japan for the antiplatelet agent Efient for the treatment of patients with ischemic heart disease undergoing percutaneous coronary intervention (PCI). Read more...

EU Approves New Thyroid Cancer Indication for Cometriq

March 25, 2014 10:31 am | News | Comments

Exelixis Inc. announced that the European Commission has approved Cometriq (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC). Read more...     

Agios Enrolls First Patient in Phase 1 Cancer Trial

March 24, 2014 3:23 pm | News | Comments

Agios Pharmaceuticals Inc. announced dose administration for the first patient in a Phase 1 study of AG-120 in patients with advanced solid tumors with an isocitrate dehydrogenase-1 (IDH1) mutation. Read more...           

Statins May Provide Cough Relief to Lung Disease Patients

March 24, 2014 3:18 pm | News | Comments

Common cholesterol-lowering drugs could provide relief to patients suffering from a chronic lung disease, a study has shown. The drugs- known as statins- were found to help alleviate the chronic coughing associated with the disease for some patients. Read more...


Pfizer Releases First Phase 3 Tofacitinib Psoriasis Results

March 24, 2014 3:01 pm | News | Comments

Pfizer Inc. announced detailed results from OPT Compare, a Phase 3 study of tofacitinib, the safety and efficacy of which are being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis. Read more...     

Ariad Launches Phase 2 Lung Cancer Trial

March 24, 2014 2:46 pm | News | Comments

Ariad Pharmaceuticals Inc. announced the initiation of a pivotal global Phase 2 trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who were previously treated with crizotinib. Read more...    

Japan OKs World-First ADPKD Therapy

March 24, 2014 11:03 am | News | Comments

Otsuka Pharmaceutical Co. Ltd. announced it has become the first company in the world to obtain regulatory approval for a pharmacological treatment of autosomal dominant polycystic kidney disease (ADPKD). Read more...         

Roche Chronic Hive Drug Gets FDA Green Light

March 24, 2014 10:42 am | News | Comments

Roche announced that the FDA approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives, in people 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. Read more...

AstraZeneca Snags Forxiga Approval in Japan

March 24, 2014 10:03 am | News | Comments

AstraZeneca announced that the Japanese Ministry of Health, Labor and Welfare approved Forxiga (dapagliflozin) as a once-daily oral treatment for type 2 diabetes. Read more...                     


Simeprevir for Hepatitis C Approved in Russia

March 24, 2014 9:50 am | News | Comments

Medivir AB announced that that the Russian Ministry of Health has approved Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection. Read more...                       

FDA Approves Celgene's Specialty Arthritis Drug

March 24, 2014 9:40 am | News | Comments

The Food and Drug Administration on Friday said it approved Celgene Corp.'s drug Otezla to treat adults with psoriatic arthritis, a form of arthritis that causes joint pain, stiffness and swelling in patients with psoriasis. Read more...   

Emmaus Sickle Cell Drug Hits Phase 3 Endpoints

March 21, 2014 3:04 pm | News | Comments

Emmaus Life Sciences Inc. announced that preliminary top-line results of its Phase 3 clinical trial evaluating the safety and efficacy of its treatment for sickle cell anemia and sickle beta-0 thalassemia met both the primary and secondary endpoints of the clinical trial. Read more...

Endocyte Drug Slows Lung Cancer Progression

March 21, 2014 2:55 pm | News | Comments

Endocyte Inc. announced results from a Phase 2b trial, which showed that the study met the primary endpoint for the combination of vintafolide and docetaxel in folate receptor-positive recurrent non-small cell lung cancer patients. Read more...  

Committee OKs Expanded Use of Novo Nordisk Drugs

March 21, 2014 2:44 pm | News | Comments

The Committee for Medicinal Products for Human Use (CHMP) issued positive opinions for expanded use of Tresiba (insulin degludec) and Victoza (liraglutide) in type 2 diabetes. Read more...                  

Investigational Drug Evaluated in Newborns with Rare Disorder

March 21, 2014 2:31 pm | News | Comments

Children with a rare genetic disorder that causes missing and malformed teeth, sparse hair and the inability to perspire are born without a key developmental protein. A clinical trial now underway aims to see if the void can be filled with replacement-protein therapy. Read more...

Novartis Starting New Head-to-Head Psoriasis Trial

March 21, 2014 2:10 pm | News | Comments

Novartis announced that a new Phase 3b head-to-head study of IL-17A inhibitor secukinumab (AIN457) versus Stelara (ustekinumab) in moderate-to-severe plaque psoriasis has started patient enrollment. Read more..           

Simeprevir for Hep C Closer to EU Approval

March 21, 2014 11:19 am | News | Comments

Medivir AB announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending Marketing Authorization in the European Union for the use of simeprevir. in combination with other drugs, for the treatment of chronic hepatitis C. Read more...

Takeda's UC, Crohn's Drug Gets OK from EU Committee

March 21, 2014 11:08 am | News | Comments

Takeda announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has issued a positive opinion for Entyvio (vedolizumab) for the treatment of adults with ulcerative colitis (UC) and Crohn's disease (CD). Read more...

Oral Chemotherapy Trial Launched in New Zealand

March 21, 2014 11:00 am | News | Comments

Kinex Pharmaceuticals announced that the company has received regulatory and ethics approvals to initiate the first clinical study of an oral form of paclitaxel (Oraxol) in Dunedin Hospital in Otago, New Zealand. Read more...        

CHMP Recommends EU Approval of Empagliflozin for Diabetes

March 21, 2014 10:41 am | News | Comments

Boehringer Ingelheim and Eli Lilly and Co. announced a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, recommending approval of empagliflozin in adults with type 2 diabetes. Read more...

UK Panel Backs Bexsero for National Immunization Program

March 21, 2014 10:24 am | News | Comments

Novartis announced that the Joint Committee on Vaccination and Immunization in the UK has recommended the inclusion of Bexsero (Meningococcal Group B Vaccine) in the National Immunization Program. Read more...           

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.